{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:16:56Z","timestamp":1788405416161,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s00198-010-1448-2","type":"journal-article","created":{"date-parts":[[2010,11,29]],"date-time":"2010-11-29T12:21:14Z","timestamp":1291033274000},"page":"2337-2345","source":"Crossref","is-referenced-by-count":43,"title":["Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid"],"prefix":"10.1007","volume":"22","author":[{"given":"S. L.","family":"Silverman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kriegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Kianifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,30]]},"reference":[{"key":"1448_CR1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"1448_CR2","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809","journal-title":"N Engl J Med"},{"key":"1448_CR3","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","volume":"17","author":"T Tanvetyanon","year":"2006","unstructured":"Tanvetyanon T, Stiff PJ (2006) Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17:897\u2013907","journal-title":"Ann Oncol"},{"key":"1448_CR4","unstructured":"Reclast\u00ae (zoledronic acid) prescribing information (2009) Novartis Pharmaceuticals, East Hanover, NJ"},{"key":"1448_CR5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s002239900353","volume":"61","author":"D Thi\u00e9baud","year":"1997","unstructured":"Thi\u00e9baud D, Sauty A, Burckhardt P et al (1997) An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61:386\u2013392","journal-title":"Calcif Tissue Int"},{"key":"1448_CR6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/107999003322558782","volume":"23","author":"G Dicuonzo","year":"2003","unstructured":"Dicuonzo G, Vincenzi B, Santini D et al (2003) Fever after zoledronic acid administration is due to increase in TNF-\u03b1 and IL-6. J Interferon Cytokine Res 23:649\u2013654","journal-title":"J Interferon Cytokine Res"},{"key":"1448_CR7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2008.07435.x","volume":"144","author":"AJ Roelofs","year":"2009","unstructured":"Roelofs AJ, Jauhiainen M, M\u00f6nkk\u00f6nen H et al (2009) Peripheral blood monocytes are responsible for \u03b3\u03b4 T cell activation induced by zoledronic acid through accumulation of IPP\/DMAPP. Br J Haematol 144:245\u2013250","journal-title":"Br J Haematol"},{"issue":"19","key":"1448_CR8","doi-asserted-by":"crossref","first-page":"15961","DOI":"10.1074\/jbc.M008684200","volume":"276","author":"V Lafont","year":"2001","unstructured":"Lafont V, Liautard J, Sable-Teychene M et al (2001) Isopentenyl pyrophosphate, a mycobacterial non-peptidic antigen, triggers delayed and highly sustained signaling in human gamma delta T lymphocytes without inducing down-modulation of T cell antigen receptor. J Biol Chem 276(19):15961\u201315967","journal-title":"J Biol Chem"},{"issue":"1","key":"1448_CR9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood.V95.1.39","volume":"95","author":"B Cipriani","year":"2000","unstructured":"Cipriani B, Borsellino G, Poccia F et al (2000) Activation of C\u2013C beta-chemokines in human peripheral blood gamma delta T cells by isopentenyl pyrophosphate and regulation by cytokines. Blood 95(1):39\u201347","journal-title":"Blood"},{"key":"1448_CR10","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","volume":"103","author":"KL Kavanagh","year":"2006","unstructured":"Kavanagh KL, Guo K, Dunford JE et al (2006) The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 103:7829\u20137834","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 4","key":"1448_CR11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","volume":"9","author":"JR Green","year":"2004","unstructured":"Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9(Suppl 4):3\u201313","journal-title":"Oncologist"},{"key":"1448_CR12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1359\/JBMR.0301230","volume":"19","author":"K Thompson","year":"2004","unstructured":"Thompson K, Rogers MJ (2004) Statins prevent bisphosphonate-induced \u03b3, \u03b4-T-cell proliferation and activation in vitro. J Bone Miner Res 19:278\u2013288","journal-title":"J Bone Miner Res"},{"key":"1448_CR13","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","volume":"111","author":"MB Pepys","year":"2003","unstructured":"Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111:1805\u20131812","journal-title":"J Clin Invest"},{"key":"1448_CR14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1359\/jbmr.081016","volume":"24","author":"T Srivastava","year":"2009","unstructured":"Srivastava T, Haney CJ, Alon US (2009) Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion. J Bone Miner Res 24:334\u2013337","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00198-010-1448-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T05:04:25Z","timestamp":1592111065000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-010-1448-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,30]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["1448"],"URL":"https:\/\/doi.org\/10.1007\/s00198-010-1448-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,30]]}}}